Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin

Chikazawa, Kenro; Netsu, Sachiho; Imai, Ken; Ishiguro, Aya; Kimura, Azusa; Wang, Liangcheng; Kuwata, Tomoyuki; Konno, Ryo

doi:10.1016/j.tjog.2020.05.013

Cited by 4 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The newer compound, nedaplatin was also investigated as a substitute for patients experiencing HSR to carboplatin. A recent study confirmed the safety profile and also efficacy of nedaplatin used in this context, with only one patient experiencing an HSR to this newer analog [ 54 ].…”

Section: Antineoplastic Therapy Involved In Hypersensitivity Reactionsmentioning

confidence: 78%

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions

Gălățeanu

Puscasu

Tîrcol

et al. 2023

IJMS

View full text Add to dashboard Cite

As the backbone of oncological treatments, systemic chemotherapy is still one of the main pawns in cancer care, alone or in combination with newer targeted agents. All chemotherapy agents can be associated with a type of adverse event called an infusion reaction, which can be characterized as unpredictable, non-dose related, and unexplained by the cytotoxic profile of the drug. For some of these events, a certain immunological mechanism can be identified by blood or skin testing. In this case, we can speak of true hypersensitivity reactions that occur as a response to an antigen/allergen. The current work summarizes the main antineoplastic therapy agents and their susceptibility to induce hypersensitivity reactions and also includes a review of clinical presentation, diagnostic methods in hypersensitivity reactions, and perspectives to overcome these negative events in the treatment of patients suffering from various types of cancer.

show abstract

Section: Antineoplastic Therapy Involved In Hypersensitivity Reactionsmentioning

confidence: 78%

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions

Gălățeanu

Puscasu

Tîrcol

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…This drug can be used in patients with recurrent changes of cervical and ovarian cancer after treatment with cisplatin [56]. Nedaplatin can also be used in patients with hypersensitivity reactions to carboplatin therapy [57]. In clinical trials, nedaplatin has been shown to be highly effective pharmacologically in combination with radiotherapy, paclitaxel and irinotecan [58][59][60].…”

Section: Nedaplatinmentioning

confidence: 99%

Selected platinum complexes in standard and modern anti-cancer therapies

Kopacz-Bednarska

Król

2022

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

The constantly observed increase in the number of cancer cases inspires research aimed at searching for new compounds with anti-cancer potential. In recent years, much research has focused on platinum complexes, especially their anti-cancer properties. Platinum derivatives are characterized by high cytotoxic activity against many types of cancer cells. However, among the numerous developed complexes, only cisplatin, carboplatin and oxaliplatin have found wide application in chemotherapeutic treatment. Nedaplatin, lobaplatin and heptaplatin have also gained recognition, and have been implemented in oncological therapy in Japan, China and Korea. Some of the platinum complexes are still at the stage of pre-clinical and clinical trials. The aim of the research conducted today is to search for platinum compounds that show high pharmacological effectiveness, with clearly limited side effects. In future therapeutic strategies, the possibility of using platinum complexes in conjunction with other chemotherapeutic compounds is being considered, which may contribute to increasing the efficacy of anti-cancer therapy.

show abstract

“…Its antitumor mechanism is similar to that of cisplatin—binding with DNA, inhibiting the growth of tumor cells and producing antitumor activity[ 1 ]. It has been widely used for the treatment of head and neck, lung, esophageal, bladder, and gynecological cancers and many other malignancies[ 2 - 4 ]. The dose-limiting toxicity of nedaplatin is myelosuppression, and other common adverse reactions include gastrointestinal symptoms, kidney dysfunction, ototoxicity and alopecia[ 3 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Nedaplatin-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report and review of the literature

Tian

Zhang

2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is relatively common in several cancers, such as small cell lung cancer. However, nedaplatin-induced SIADH is rare. We describe a case of SIADH mediated by nedaplatin. CASE SUMMARY A 54-year-old female with nasopharyngeal carcinoma was treated with nedaplatin and developed severe hyponatremia due to SIADH. The side effects were successfully treated by fluid restriction and sodium supplementation. CONCLUSION This case report highlights the importance of cautiously treating life-threatening hyponatremia in patients treated with nedaplatin.

show abstract

Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin

Cited by 4 publications

References 34 publications

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions

Selected platinum complexes in standard and modern anti-cancer therapies

Nedaplatin-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report and review of the literature

Contact Info

Product

Resources

About